Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 2:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 213 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Triamcinolone Injection Clear all
Completed Phase 1Phase 2 Interventional Results available

The Transendocardial Autologous Cells (hMSC or hBMC) in Ischemic Heart Failure Trial (TAC-HFT)

NCT00768066
View directory record Official record
Conditions
Stem Cell Transplantation, Ventricular Dysfunction, Left
Interventions
Autologous human mesenchymal cells (hMSCs), Autologous human bone marrow cells (hBMCs), Placebo
Biological
Lead sponsor
University of Miami
Other
Eligibility
21 Years to 90 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 14, 2015 · Synced Oct 20, 2026, 2:22 PM EDT
Recruiting Phase 4 Interventional

Frozen Shoulder and Hormone Replacement Therapy

NCT07278323
View directory record Official record
Conditions
Adhesive Capsulitis of the Shoulder, Frozen Shoulder
Interventions
Hormone Replacement Therapy (HRT), Corticosteroid and 1%lidocain, physical therapy
Drug · Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
40 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 20, 2026, 2:22 PM EDT
Completed Phase 2 Interventional Results available

Study to Compare Exposure of TA Following Administration of Either FX006 or TAcs in Patients With Bilateral Knee OA

NCT03378076
View directory record Official record
Conditions
Bilateral Knee Osteoarthritis
Interventions
FX006 32 mg, TAcs 40 mg
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
40 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
3
States / cities
Torrance, California • Rochester, New York • Duncansville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 24, 2024 · Synced Oct 20, 2026, 2:22 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Effect of FX006 on Synovial Inflammation in Patients With OA of the Knee

NCT03529942
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
FX006 32 mg
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
40 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
9
States / cities
El Cajon, California • La Mesa, California • Pomona, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2024 · Synced Oct 20, 2026, 2:22 PM EDT
Completed Phase 3 Interventional

Steroid Injections vs. Standard Treatment for Macular Edema Due to Retinal Blood Vessel Blockage

NCT00106132
View directory record Official record
Conditions
Retinal Vein Occlusion, Macular Edema, Cystoid, Macular Edema
Interventions
Triamcinolone Acetonide
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
1,260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 20, 2026, 2:22 PM EDT
Completed Phase 3 Interventional Results available

Efficacy of EUS-guided Celiac Plexus Blockade in Chronic Pancreatitis

NCT00658736
View directory record Official record
Conditions
Chronic Pancreatitis
Interventions
Triamcinolone, Bupivicaine alone
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 20, 2026, 2:22 PM EDT
Recruiting Early Phase 1 Interventional

Efficacy of Intramuscular Steroid Injection for Chronic Cough.

NCT06634823
View directory record Official record
Conditions
Chronic Cough (CC), Laryngeal Disease, Coughing
Interventions
Triamcinolone Acetonide Injectable Suspension, Saline injection
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 20, 2026, 2:22 PM EDT
Completed Phase 2 Interventional Results available

Ranibizumab and Peripheral Scatter Laser in Patients With Diabetic Macular Edema and Peripheral Nonperfusion

NCT00815360
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
intravitreal injection of ranibizumab, peripheral laser, intravitreal injection of triamcinolone acetonide, macular laser
Drug · Procedure
Lead sponsor
Retina Associates of Florida, P.A.
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 5, 2015 · Synced Oct 20, 2026, 2:22 PM EDT
Active, not recruiting Phase 3 Interventional

ZILRETTA in Subjects With Shoulder Osteoarthritis

NCT06269705
View directory record Official record
Conditions
Glenohumeral Osteoarthritis
Interventions
ZILRETTA, Placebo
Drug · Other
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
50 Years to 80 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
32
States / cities
Vestavia Hills, Alabama • Surprise, Arizona • Tucson, Arizona + 29 more
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 20, 2026, 2:22 PM EDT
Completed Phase 3 Interventional Results available

Suprachoroidal Injection of CLS-TA in Patients With Non-infectious Uveitis

NCT03097315
View directory record Official record
Conditions
Uveitis, Uveitis, Posterior, Uveitis, Anterior, Uveitis, Intermediate, Panuveitis
Interventions
4 mg CLS-TA Suprachoriodal Injection
Drug
Lead sponsor
Clearside Biomedical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
10
States / cities
Phoenix, Arizona • Beverly Hills, California • Mountain View, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2021 · Synced Oct 20, 2026, 2:22 PM EDT
Completed Phase 4 Interventional Results available

IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA

NCT02451748
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Lab Work, Certolizumab pegol (CDP870, tradename Cimzia)(prefilled syringes at the dose of 200mg), Certolizumab pegol (CDP870, tradename Cimzia), Hydroxychloroquine, Sulfasalazine, Medrol, Prednisone, Triamcinolone, Naproxen, Leflunomide, Methotrexate, humira
Other · Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 10, 2024 · Synced Oct 20, 2026, 2:22 PM EDT
Not listed Phase 1Phase 2 Interventional

Mesenchymal Stem Cell Therapy for Knee Osteoarthritis

NCT05288725
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
Bone Marrow Derived MSCs, Corticosteroid, Bone Marrow Aspirate
Biological · Drug · Device
Lead sponsor
Next Generation Regenerative Medicine LLC
Network
Eligibility
18 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
3
States / cities
Chesterfield, Missouri • Steubenville, Ohio • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 21, 2022 · Synced Oct 20, 2026, 2:22 PM EDT
Terminated Phase 1Phase 2 Interventional

Biological Response to Platelet-rich Plasma and Corticosteroid Injections

NCT05657496
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Triamcinolone Acetonide 40 mg/ml Inj, Susp, Platelet-rich plasma Inj
Drug · Biological
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
40 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 25, 2025 · Synced Oct 20, 2026, 2:22 PM EDT
Completed Phase 2 Interventional Results available

Symptom Clusters in Children With Exacerbation-prone Asthma

NCT04002362
View directory record Official record
Conditions
Asthma in Children
Interventions
Triamcinolone Acetonide
Drug
Lead sponsor
Emory University
Other
Eligibility
6 Years to 21 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 20, 2026, 2:22 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Optimal Anesthetic for Corticosteroid Injections for Knee Osteoarthritis

NCT05906433
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Kenalog with bupivacaine Injection
Drug
Lead sponsor
Foundation for Orthopaedic Research and Education
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 20, 2026, 2:22 PM EDT
Active, not recruiting Phase 4 Interventional

Corticosteroid Meniscectomy Randomized Trial

NCT04641351
View directory record Official record
Conditions
Osteoarthritis, Knee, Meniscus Tear, Meniscus; Degeneration, Synovitis
Interventions
Zilretta Injectable Product or Placebo
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
40 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 20, 2026, 2:22 PM EDT
Completed Not applicable Interventional Results available

Onabotulinumtoxin A Versus Kenalog for Chronic Pelvic Pain

NCT02369068
View directory record Official record
Conditions
Pelvic Pain
Interventions
Onabotulinumtoxin A, Kenalog
Drug
Lead sponsor
Jamie Bartley, DO
Other
Eligibility
18 Years and older · Female only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 24, 2019 · Synced Oct 20, 2026, 2:22 PM EDT
Terminated Phase 1 Interventional

Platelet Rich Plasma vs. Corticosteroid Injection in the Treatment of Partial Rotator Cuff Tears

NCT01688362
View directory record Official record
Conditions
Rotator Cuff Tear
Interventions
Platelet Rich Plasma (PRP), Corticosteroid
Biological · Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Oct 20, 2026, 2:22 PM EDT
Enrolling by invitation Phase 4 Interventional

Comparing Treatment of Knee Osteoarthritis With Triamcinolone Injections Using 40mg With Landmark Guidance and 20mg With Ultrasound Guidance

NCT07544576
View directory record Official record
Conditions
Knee Arthritis Osteoarthritis
Interventions
Triamcinolone knee injection without ultrasound guidance, Triamcinolone knee injection with ultrasound guidance
Drug · Combination Product
Lead sponsor
Sosi Dzhugarian
Other
Eligibility
50 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
4
States / cities
Ventura, California
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 20, 2026, 2:22 PM EDT
Withdrawn Not applicable Interventional

Effect of Celiac Plexus Block on Gastric Emptying and Symptoms Caused by Gastroparesis

NCT02420925
View directory record Official record
Conditions
Gastroparesis
Interventions
Celiac Plexus Block
Procedure
Lead sponsor
Linda Nguyen
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 28, 2020 · Synced Oct 20, 2026, 2:22 PM EDT
Completed Phase 2 Interventional

A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

NCT05811351
View directory record Official record
Conditions
Geographic Atrophy
Interventions
JNJ-81201887, Prednisone, Placebo, Triamcinolone, Sham Procedure
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
60 Years and older
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
79
States / cities
Phoenix, Arizona • Tucson, Arizona • Fullerton, California + 66 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 20, 2026, 2:22 PM EDT
Completed Not applicable Interventional Results available

Comparing the Effects of Ultrasound Versus Fluoroscopy for Sacroiliac Joint Injections

NCT02420041
View directory record Official record
Conditions
Sacroiliitis
Interventions
Active comparator: Fluoroscopic Guided SIJ injection, Ultrasound Guided Sacroiliac Joint Injection, Havel's Inc. EchoStim (facet tip) 21 Gauge 4" needle, SonoSite S-nerve, iohexol, triamcinolone/lidocaine
Procedure · Device · Drug
Lead sponsor
United States Naval Medical Center, San Diego
Federal
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Nov 13, 2015 · Synced Oct 20, 2026, 2:22 PM EDT
Terminated Phase 2 Interventional Results available

Success of Long-acting Anti-inflammatories After Anterior Cruciate Ligament and Meniscal Injury

NCT04331002
View directory record Official record
Conditions
Tibial Meniscus Injuries, Tibial Meniscus Tears, Tibial Meniscus, Torn, Anterior Cruciate Ligament Tear
Interventions
Zilretta, Placebo
Drug · Other
Lead sponsor
Austin V Stone
Other
Eligibility
18 Years to 40 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 20, 2026, 2:22 PM EDT
Terminated Phase 4 Interventional Results available

Trial Comparing Three Single Dose Injections for Knee Osteoarthritis

NCT05492851
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
Zilretta, Synvisc-One 48 MG in 6 ML Prefilled Syringe, Monovisc 88 MG Per 4 ML Prefilled Syringe
Drug
Lead sponsor
Ohio State University
Other
Eligibility
25 Years to 85 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
Columbus, Ohio • Lewis Center, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 20, 2026, 2:22 PM EDT